Abstract
Even though intra-arterial fibrinolysis has shown a significantly better outcome in the Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial, this treatment option was not approved by the US Food and Drug Administration (FDA), whereas intravenous fibrinolysis was approved as a standard therapy. New mechanical endovascular approaches, such as the Merci device or the Penumbra system were initially seen with great enthusiasm in the neuro-interventional community as high recanalization rates of up to 80% were achieved. Nevertheless, clinical results were disappointing which is why these techniques were increasingly critically viewed by stroke neurologists. In recent years a new technique with stent-like retrievers, has changed the practice in many stroke centers. In single center experiences even higher recanalization rates have been reported which were also associated with improved outcome in a substantial number of patients. This is a posi
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
